Fig. 1From: A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaSwimmer plot of treatment duration by CXD101 dose and tumour histology * Recommended Phase 2 doseBack to article page